scholarly journals Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

Oncotarget ◽  
2016 ◽  
Vol 7 (47) ◽  
pp. 76604-76612 ◽  
Author(s):  
Hyerim Ha ◽  
Ah-Rong Nam ◽  
Ju-Hee Bang ◽  
Ji-Eun Park ◽  
Tae-Yong Kim ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Palliative Chemotherapy ◽  
Neutrophil To Lymphocyte Ratio ◽  
Programmed Death Ligand 1 ◽  
Lymphocyte Ratio ◽  
Tract Cancer ◽  
Programmed Death

Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 416-416
Author(s):  
Kyoung Min Cho ◽  
Hyunkyung Park ◽  
Do-Youn Oh ◽  
Tae Yong Kim ◽  
Kyung-Hun Lee ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Systemic Inflammation ◽  
Biliary Tract Cancer ◽  
Palliative Chemotherapy ◽  
Dynamic Change ◽  
Neutrophil To Lymphocyte Ratio ◽  
Platelet To Lymphocyte Ratio ◽  
Primary Tumor Site ◽  
Lymphocyte Ratio ◽  
Tract Cancer

416 Background: Systemic inflammation is known to promote carcinogenesis in biliary tract cancer (BTC). Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are indicative of systemic inflammation. We evaluated the clinical significance of systemic inflammation measured by NLR and PLR in patients with advanced BTC. Additionally, we also co-analyzed the dynamics of NLR and PLR during chemotherapy. Methods: We reviewed 554 patients with advanced BTC receiving palliative chemotherapy. NLR and PLR were obtained before initiation of palliative chemotherapy. Changes in NLR, PLR were obtained by subtracting the initial value from the value obtained after progression of chemotherapy. Results: Higher systemic inflammation status also had relation with a primary tumor site ( p = 0.044) and higher levels of CEA ( p = 0.041). The ROC cut-off values of NLR and PLR for predicting overall survival (OS) were 3.8 and 121, respectively. Patients with a high NLR or PLR had worse OS independently in multivariate analysis (7.10 vs. 10.23 months, p < 0.001; 8.43 vs. 11.87 months, p = 0.001, respectively). High NLR with increased NLR after chemotherapy is associated with worse OS and progression-free survival (PFS) ( p = 0.014, p= 0.020 respectively). Results are similar for PLR. Conclusions: Systemic inflammation represented by NLR and PLR, predicts the OS of patients with advanced BTC who are receiving palliative chemotherapy. In addition, considering NLR/PLR with a dynamic change of NLR/PLR during chemotherapy might help to predict a more accurate prognosis.

scholarly journals Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis

Aging ◽  
2019 ◽  
Vol 11 (24) ◽  
pp. 12568-12580
Author(s):  
Changjiang Lei ◽  
Xiulan Peng ◽  
Xiaojun Gong ◽  
Ying Fan ◽  
Shenglin Wu ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Meta Analysis ◽  
Prognostic Role ◽  
Programmed Death Ligand 1 ◽  
Tract Cancer ◽  
Programmed Death

scholarly journals Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Lukas Müller ◽  
Aline Mähringer-Kunz ◽  
Florian Jungmann ◽  
Yasemin Tanyildizi ◽  
Fabian Bartsch ◽  
...  
Keyword(s):  
Risk Stratification ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Significant Risk ◽  
Minor Component ◽  
Neutrophil To Lymphocyte Ratio ◽  
Brier Score ◽  
Clinical Registry ◽  
Lymphocyte Ratio ◽  
Tract Cancer

Background. In addition to the clinical parameters, immune-inflammatory markers have emerged as prognostic factors in patients with advanced biliary tract cancer (ABC). The recently proposed A.L.A.N. score combines both in an easily applicable manner. The aim of this study was to perform the first external evaluation of this score. Methods. All patients from our clinical registry unit who had unresectable ABC underwent first-line chemotherapy from 2006 to 2018 and met the inclusion criteria of the original study were included (n =  74). The A.L.A.N. score comprises the following parameters: actual neutrophil count, lymphocyte-to-monocyte ratio, albumin, and neutrophil-to-lymphocyte ratio (A.L.A.N.). Univariate and multivariate hazard regression analyses were performed to evaluate the score’s parameters regarding overall survival (OS). The concordance index (C-index) and integrated Brier score (IBS) were calculated to evaluate the score’s predictive performance. Results. Low, intermediate, and high A.L.A.N. scores corresponded to median OS of 21.9, 11.4, and 4.3 months, respectively, resulting in a significant risk stratification (log-rank p=0.017). In multivariate analysis, a high-risk A.L.A.N. score remained an independent predictor of poor survival (p=0.016). Neutrophil-to-lymphocyte ratio was not a significant factor for poor OS in the analyses in the cohort. The score’s ability to predict individual patient survival was only moderate with a C-index of 0.63. Conclusions. The A.L.A.N. score can be used to identify risk groups with a poor prognosis prior to the start of chemotherapy. However, the ability of the score to predict individual patient outcome was only moderate; thus, it may only serve as a minor component in the complex interdisciplinary discussion.

Preoperative Neutrophil-to-lymphocyte Ratio Predicts Tumor-infiltrating CD8+ T Cells in Biliary Tract Cancer

2020 ◽  
Vol 40 (5) ◽  
pp. 2881-2887
Author(s):  
RYOTA TANAKA ◽  
KENJIRO KIMURA ◽  
SHINPEI EGUCHI ◽  
JUN TAUCHI ◽  
MASATUNE SHIBUTANI ◽  
...  
Keyword(s):  
T Cells ◽  
Biliary Tract ◽  
Cd8 T Cells ◽  
Biliary Tract Cancer ◽  
Neutrophil To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Tract Cancer

The prognostic role of soluble transforming growth factor-β (sTGFb) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 257-257
Author(s):  
Jin Won Kim ◽  
Kyung-Hun Lee ◽  
Ji-Won Kim ◽  
Koung Jin Suh ◽  
Ah-Rong Nam ◽  
...  
Keyword(s):  
Growth Factor ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Transforming Growth Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Prognostic Role ◽  
Programmed Death Ligand 1 ◽  
Positive Correlation ◽  
Tract Cancer ◽  
Programmed Death

257 Background: Transforming growth factor (TGF) -β signaling is important for tumor growth and metastasis in biliary tract cancer (BTC). TGF-β attenuates tumor response to programmed death-ligand 1 (PD-L1) blockade. This study aimed to evaluate a correlation between soluble TGF-β (s TGF-β) and soluble PD-L1 (sPD-L1) and its prognostic role in BTC. Methods: Study population consisted of 34 patients enrolled in phase Ib clinical trial of binimetinib (MEK inhibitor) with capecitabine in gemcitabine-pretreated BTC (ClinicalTrials.gov: NCT02773459). Blood samples at screening, after first cycle, after second cycle, and at disease progression were prospectively collected. Plasma sTGF-β and sPD-L1 values were measured by using an enzyme-linked immunosorbent assay. Results: In total 34 patients, 25 (73.5%) and 9 patients (26.5%) were second-line and third-line setting, respectively. Median progression-free survival (PFS) and overall survival (OS) were 4.1 and 7.8 months. The mean baseline sTGF-β and sPD-L1 were 18.7 ng/ml and 3.1 ng/ml. There was a positive correlation between sTGF-β and sPD-L1 value (pearson correlation = 0.596, p < 0.001). Mean baseline value was likely to be higher in best response of progressive disease, followed by stable disease and partial response. Similarly, higher baseline sTGF-β showed significantly shorter PFS (3.4 vs 5.1 months (m), p = 0.047) and OS (5.4 vs 9.7 m, p = 0.042). Higher baseline sPD-L1 also had a trend for poor PFS and OS (PFS: 3.0 vs 4.3 m, p = 0.220; OS: 6.4 vs 9.7 m, p = 0.140). Regarding changes from baseline to after first cycle, sTGF-β change of > 3.6 ng/ml demonstrated significantly shorter OS (5.9 vs 10.8 m, p = 0.020), although PFS did not differ according to sTGF-β change (p = 0.210). In contrast, OS did not differ according to sPD-L1 change (p = 0.190). sPD-L1 change > -1.7 ng/ml even had longer PFS (5.1 vs 2.2 m, p = 0.005). Conclusions: In BTC patients with binimetinib and capecitabine, there is a positive correlation between sTGF-β and sPD-L1 value and higher baseline sTGF-β and sPD-L1 indicate a worse prognosis. The early change of sTGF-β and sPD-L1 during treatment could predict the survival.

Association Between Body Mass Index and Prognosis in Advanced Biliary Tract Cancer Patients Who Underwent Palliative Chemotherapy

2017 ◽  
Vol 152 (5) ◽  
pp. S299-S300
Author(s):  
Jinwoo Kang ◽  
Sang Hyub Lee ◽  
Jae Woo Lee ◽  
Jun Hyuk Son ◽  
Ji Kon Ryu ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Cancer Patients ◽  
Body Mass ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Palliative Chemotherapy ◽  
Tract Cancer

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer

Oncology ◽  
2021 ◽  
pp. 1-8
Author(s):  
Hyera Kim ◽  
Jinchul Kim ◽  
Seonggyu Byeon ◽  
Kee-Taek Jang ◽  
Jung Yong Hong ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Checkpoint Inhibitors ◽  
Progression Free Survival ◽  
Tumor Location ◽  
Extrahepatic Cholangiocarcinoma ◽  
Programmed Death Ligand 1 ◽  
Tract Cancer ◽  
Programmed Death ◽  
Combined Positive Score

Background: Biliary tract cancer (BTC) is associated with poor prognosis because of its aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been considered a novel biomarker for prognosis and response of immune checkpoint inhibitors in various tumors. However, there are limited data reporting on the role of PD-L1 in advanced BTC patients. Patients and Methods: We analyzed 186 patients with advanced BTC who received palliative gemcitabine and platinum between May 2010 and December 2019. All patients were evaluated for PD-L1 expression by combined positive score positivity. Results: Of the 186 patients, the primary tumor location was intrahepatic cholangiocarcinoma (IHCC) in 72 (38.7%), extrahepatic cholangiocarcinoma (EHCC) in 90 (48.4%), and gallbladder (GB) cancer in 24 (12.9%). Among all the patients, 53 (28.5%) had PD-L1 positivity. The median overall survival (OS) of patients with PD-L1 positivity or negativity was 12.1 and 15.4 months, respectively. The median progression-free survival (PFS) in patients with PD-L1 positivity or negativity was 5.7 and 7.1 months, respectively. OS and PFS were not statistically different between groups. In subgroup analysis, EHCC patients with PD-L1 negativity had more favorable OS (17.2 vs. 11.6 months, p = 0.002) and PFS (7.8 vs. 5.4 months, p = 0.005) than those who were PD-L1-positive. However, this finding was not reproduced in patients with IHCC or GB cancer. Conclusion: This study demonstrated that PD-L1 expression might be a novel prognostic biomarker in patients with EHCC but not in patients with IHCC or GB cancer.

Sign in / Sign up

Export Citation Format

Share Document